Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

N Girard; L Greillier; G Zalcman; J Cadranel; D Moro-Sibilot; J Mazières; C Audigier-Valette; J Bennouna; B Besse; A Cortot; S Couraud; M Duruisseaux; E Giroux-Leprieur; A-C Toffart; V Westeel; M Wislez; French-Language Society of Pulmonology SPLF French-language Oncology Group

doi:10.1016/j.resmer.2020.100769

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

Respir Med Res. 2020 Nov:78:100769. doi: 10.1016/j.resmer.2020.100769. Epub 2020 May 24.

Authors

N Girard¹, L Greillier², G Zalcman³, J Cadranel⁴, D Moro-Sibilot⁵, J Mazières⁶, C Audigier-Valette⁷, J Bennouna⁸, B Besse⁹, A Cortot¹⁰, S Couraud¹¹, M Duruisseaux¹¹, E Giroux-Leprieur¹², A-C Toffart⁵, V Westeel¹³, M Wislez¹⁴; French-Language Society of Pulmonology SPLF French-language Oncology Group

Affiliations

¹ Department of Medical Oncology, Institut Curie, 75005 Paris, France. Electronic address: Nicolas.girard2@curie.fr.
² Aix-Marseille Université, AP-HM, INSERM, CNRS, CRCM, Hôpital Nord, Multidisciplinary Oncology and Therapeutic Innovations Department, 13915 Marseille, France.
³ Department of Thoracic Oncology, CIC 1425, AP-HP, Hôpital Bichat-Claude-Bernard, 75018 Paris, France.
⁴ Department of Thoracic Oncology, AP-HP, Hôpital Tenon, 75020 Paris, France.
⁵ Department of Pneumology, University Hospital of Grenoble, 38043 Grenoble, France.
⁶ Department of Pneumology, University Hospital of Toulouse, 31059 Toulouse, France.
⁷ Department of Pneumology, Hôpital Sainte-Musse, 83100 Toulon, France.
⁸ Department of Medical Oncology, University Hospital of Nantes, 44000 Nantes, France.
⁹ Department of Medical Oncology, Institut Gustave-Roussy, 94800 Villejuif, France.
¹⁰ Department of Pneumology, University Hospital of Lille, 59000 Lille, France.
¹¹ Department of Pneumology and Thoracic Oncology, University Hospital of Lyon, 69002 Lyon, France.
¹² Department of Thoracic Oncology, AP-HP, Hôpital Ambroise-Paré, 92100 Boulogne-Billancourt, France.
¹³ Department of Pneumology and Thoracic Oncology, University Hospital of Besançon, INSERM UMR 1098, Université de Franche-Comté, 25000 Besançon, France.
¹⁴ Department of Thoracic Oncology, AP-HP, Hôpital Cochin, Inserm UMR_S 1138, Université de Paris, 75014 Paris, France.

Abstract

The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.

Publication types

Practice Guideline

MeSH terms

Antineoplastic Agents / therapeutic use
COVID-19 / complications
COVID-19 / epidemiology*
COVID-19 / prevention & control*
Chemoradiotherapy / methods
Chemoradiotherapy / standards
Clinical Trials as Topic / methods
Clinical Trials as Topic / organization & administration
Clinical Trials as Topic / standards
Humans
Mutation
Neoadjuvant Therapy / methods
Neoadjuvant Therapy / standards
Neoplasm Metastasis
Pandemics*
Pulmonary Medicine / methods
Pulmonary Medicine / organization & administration
Pulmonary Medicine / standards
Risk Factors
Risk Reduction Behavior
SARS-CoV-2
Thoracic Neoplasms / epidemiology
Thoracic Neoplasms / genetics
Thoracic Neoplasms / pathology
Thoracic Neoplasms / therapy*
Thoracic Surgical Procedures / methods
Thoracic Surgical Procedures / standards

Substances

Antineoplastic Agents